{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:25:24Z","timestamp":1791275124810,"version":"4.1.0"},"reference-count":23,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2006,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The most important antigen component of a promising multicomponent group B meningococcal recombinant protein vaccine is based on genome-derived neisserial antigen 1870, which recently was renamed factor H-binding protein (FHBP) to reflect one of its critical functions as a complement regulatory protein.\n            <jats:italic>Neisseria meningitidis<\/jats:italic>\n            strains can be subdivided into three FHBP variant groups based on divergence of FHBP amino acid sequences. Within each variant group, amino acid sequences are &gt;90% conserved. To develop an FHBP-based group B vaccine, it is important to know the distribution of FHBP variant 1, 2, and 3 strains in different geographic regions, since antibodies against FHBP are bactericidal against strains within the homologous group but show minimal activity against strains from other groups. We have devised a high-throughput, quantitative PCR-based method that allows rapid and precise assignment of FHBP genes into each of the three major variant lineages. Among 48 group B isolates from patients hospitalized in California in 2003 to 2004, 83%, 13%, and 4%, respectively, had variant 1, 2, and 3 genes. Thus, a vaccine based on the variant 1 protein has the potential to prevent the majority of cases of group B disease. The quantitative PCR-based method will be useful for determining and monitoring the prevalence of meningococcal isolates with genes encoding different FHBP variant proteins. The technique also is suitable for monitoring variation of genes encoding other protein antigens targeted for vaccination.\n          <\/jats:p>","DOI":"10.1128\/cvi.00097-06","type":"journal-article","created":{"date-parts":[[2006,7,7]],"date-time":"2006-07-07T19:12:52Z","timestamp":1152299572000},"page":"758-763","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":27,"title":["Rapid Genetic Grouping of Factor H-Binding Protein (Genome-Derived Neisserial Antigen 1870), a Promising Group B Meningococcal Vaccine Candidate"],"prefix":"10.1128","volume":"13","author":[{"given":"Peter T.","family":"Beernink","sequence":"first","affiliation":[{"name":"Children's Hospital Oakland Research Institute, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunas","family":"Leipus","sequence":"additional","affiliation":[{"name":"Children's Hospital Oakland Research Institute, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan M.","family":"Granoff","sequence":"additional","affiliation":[{"name":"Children's Hospital Oakland Research Institute, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2144\/04362BM02","volume":"36","year":"2004","unstructured":"Brody, J. R., and S. E. Kern. 2004. Sodium boric acid: a Tris-free, cooler conductive medium for DNA electrophoresis. BioTechniques36:214-216.","journal-title":"BioTechniques"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1016\/S0264-410X(01)00205-5","volume":"19","year":"2001","unstructured":"Cartwright, K., N. Noah, and H. Peltola. 2001. Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6-8 October, 2000. Vaccine19:4347-4356.","journal-title":"Vaccine"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1093\/nar\/gkg500","volume":"31","year":"2003","unstructured":"Chenna, R., H. Sugawara, T. Koike, R. Lopez, T. J. Gibson, D. G. Higgins, and J. D. Thompson. 2003. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res.31:3497-3500.","journal-title":"Nucleic Acids Res."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1084\/jem.20020407","volume":"195","year":"2002","unstructured":"Comanducci, M., S. Bambini, B. Brunelli, J. Adu-Bobie, B. Arico, B. Capecchi, M. M. Giuliani, V. Masignani, L. Santini, S. Savino, D. M. Granoff, D. A. Caugant, M. Pizza, R. Rappuoli, and M. Mora. 2002. NadA, a novel vaccine candidate of Neisseria meningitidis. J. Exp. Med.195:1445-1454.","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/infdis\/159.4.686","volume":"159","year":"1989","unstructured":"Crowe, B. A., R. A. Wall, B. Kusecek, B. Neumann, T. Olyhoek, H. Abdillahi, M. Hassan-King, B. M. Greenwood, J. T. Poolman, and M. Achtman. 1989. Clonal and variable properties of Neisseria meningitidis isolated from cases and carriers during and after an epidemic in The Gambia, West Africa. J. Infect. Dis.159:686-700.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.4.2088-2100.2004"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.2.1151-1160.2005"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.vaccine.2005.11.006","volume":"24","year":"2006","unstructured":"Jacobsson, S., S. Thulin, P. Molling, M. Unemo, M. Comanducci, R. Rappuoli, and P. Olcen. 2006. Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens. Vaccine24:2161-2168.","journal-title":"Vaccine"},{"key":"e_1_3_2_10_2","unstructured":"J. Immunol."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1086\/517385","volume":"177","year":"1998","unstructured":"Martin, D. R., S. J. Walker, M. G. Baker, and D. R. Lennon. 1998. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J. Infect. Dis.177:497-500.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20021911","volume":"197","year":"2003","unstructured":"Masignani, V., M. Comanducci, M. M. Giuliani, S. Bambini, J. Adu-Bobie, B. Arico, B. Brunelli, A. Pieri, L. Santini, S. Savino, D. Serruto, D. Litt, S. Kroll, J. A. Welsch, D. M. Granoff, R. Rappuoli, and M. Pizza. 2003. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med.197:789-799.","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/0140-6736(91)91297-8","volume":"337","year":"1991","unstructured":"McGuinness, B. T., I. N. Clarke, P. R. Lambden, A. K. Barlow, J. T. Poolman, D. M. Jones, and J. E. Heckels. 1991. Point mutation in meningococcal porA gene associated with increased endemic disease. Lancet337:514-517.","journal-title":"Lancet"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/35006655"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/00006454-200004000-00012","volume":"19","year":"2000","unstructured":"Pastor, P., F. B. Medley, and T. V. Murphy. 2000. Meningococcal disease in Dallas County, Texas: results of a six-year population-based study. Pediatr. Infect. Dis. J.19:324-328.","journal-title":"Pediatr. Infect. Dis. J."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","volume":"287","year":"2000","unstructured":"Pizza, M., V. Scarlato, V. Masignani, M. M. Giuliani, B. Arico, M. Comanducci, G. T. Jennings, L. Baldi, E. Bartolini, B. Capecchi, C. L. Galeotti, E. Luzzi, R. Manetti, E. Marchetti, M. Mora, S. Nuti, G. Ratti, L. Santini, S. Savino, M. Scarselli, E. Storni, P. Zuo, M. Broeker, E. Hundt, B. Knapp, E. Blair, T. Mason, H. Tettelin, D. W. Hood, A. C. Jeffries, N. J. Saunders, D. M. Granoff, J. C. Venter, E. R. Moxon, G. Grandi, and R. Rappuoli. 2000. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science287:1816-1820.","journal-title":"Science"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.5858\/2002-126-1209-EOADPC","volume":"126","year":"2002","unstructured":"Pollard, A. J., G. Probe, C. Trombley, A. Castell, S. Whitehead, J. M. Bigham, S. Champagne, J. Isaac-Renton, R. Tan, M. Guiver, R. Borrow, D. P. Speert, and E. Thomas. 2002. Evaluation of a diagnostic polymerase chain reaction assay for Neisseria meningitidis in North America and field experience during an outbreak. Arch. Pathol. Lab. Med.126:1209-1215.","journal-title":"Arch. Pathol. Lab. Med."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1086\/315158","volume":"180","year":"1999","unstructured":"Rosenstein, N. E., B. A. Perkins, D. S. Stephens, L. Lefkowitz, M. L. Cartter, R. Danila, P. Cieslak, K. A. Shutt, T. Popovic, A. Schuchat, L. H. Harrison, and A. L. Reingold. 1999. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J. Infect. Dis.180:1894-1901.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1590\/S0036-46651998000200009","volume":"40","year":"1998","unstructured":"Sacchi, C. T., A. P. de Lemos, A. M. Whitney, C. E. Melles, C. A. Solari, C. E. Frasch, and L. W. Mayer. 1998. The use of oligonucleotide probes for meningococcal serotype characterization. Rev. Inst. Med. Trop. Sao Paulo40:113-117.","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.5.6.845-855.1998"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1126\/science.287.5459.1809","volume":"287","year":"2000","unstructured":"Tettelin, H., N. J. Saunders, J. Heidelberg, A. C. Jeffries, K. E. Nelson, J. A. Eisen, K. A. Ketchum, D. W. Hood, J. F. Peden, R. J. Dodson, W. C. Nelson, M. L. Gwinn, R. DeBoy, J. D. Peterson, E. K. Hickey, D. H. Haft, S. L. Salzberg, O. White, R. D. Fleischmann, B. A. Dougherty, T. Mason, A. Ciecko, D. S. Parksey, E. Blair, H. Cittone, E. B. Clark, M. D. Cotton, T. R. Utterback, H. Khouri, H. Qin, J. Vamathevan, J. Gill, V. Scarlato, V. Masignani, M. Pizza, G. Grandi, L. Sun, H. O. Smith, C. M. Fraser, E. R. Moxon, R. Rappuoli, and J. C. Venter. 2000. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science287:1809-1815.","journal-title":"Science"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1099\/mic.0.26131-0","volume":"149","year":"2003","unstructured":"Thompson, E. A., I. M. Feavers, and M. C. Maiden. 2003. Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology149:1849-1858.","journal-title":"Microbiology"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.60.8.3156-3161.1992"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.4049\/jimmunol.172.9.5606","volume":"172","year":"2004","unstructured":"Welsch, J. A., R. Rossi, M. Comanducci, and D. M. Granoff. 2004. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J. Immunol.172:5606-5615.","journal-title":"J. Immunol."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00097-06","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00097-06","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:37:13Z","timestamp":1627591033000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00097-06"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["10.1128\/CVI.00097-06"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00097-06","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7]]},"assertion":[{"value":"2006-03-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-05-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}